Table 4.

Case series of patient outcomes.

Case	Age/Sex	Prior MDS/MPN	Relapsed/ Refractory	CR1 duration	Cytogenetics	Dose level	Response	Maintenance cycles	Total Cycles
1	72/F	No	Relapsed	20 mo	46,XX	1	SD	0	4
2	58/F	No	Relapsed	4 mo	45,XX,add(2)(q31), −3,−4,−5,add(7)(q21), der(16)del(16) (p13.1)del(16)(q21),−1 7,del(20)(q13.1),+21,+mar1, +mar2[14]/nonclonal w/clonal abnormalities[1]//46,XY[5]	1	<5% blasts	1	3
3	74/F	MDS	Secondary	NA	47,XX,+11[8]/48, sl,+8[5]/46,XX[7]	1	PD	0	4
4	57/F	No	Relapsed/Refractory	3 mo	46,XX	2	PD	0	2
5	66/M	No	De Novo	NA	44,XY,del(5)(q13), −10,idic(11)(p11.2),−17,−18,der(18) t(10;18)(q21;q12)[6]/4 4,sl,del(2)(q31)[3]/44, sl,add(18)(p11.2) [3]/44-45,sl,-idic(11),+tric(?;11;11) (?::11q23.1 > 11p11. 2::11p11.2 > 11qter[cp2]/nonclonal w/clonal abnormalities[1]/46, XY[5].ishidic(11)(MLL++), tric(?;11;11)(MLL+)	2	PD	0	2
6	18/M	De Novo	Relapsed	8mo	Complex	2	SD, 50% blasts post cycle 1	0	1
7	79/M	No	Refractory	NA	46,XY,inv(3)(q21q26.2), der(7)del(7)(p11)del(7) (q11.1)[20].nucish(D7Z1x2, D7S486x1)[131/209]	3	Unknown	0	1
8	73/F	No	Refractory	NA	46, XX	3	<5% blasts	1	4
9	73/M	No	De Novo	NA	46,XY,add(2) (p24),t(5;8)(q33;q13), del(12)(q22q24.1) [25].ishadd(2)(ALK+), t(5;8)(CMYC+;CMYC−)	3	CR	6+	8+
10	70/F	No	De Novo	NA	46,XX,t(1;15) (p36.3;q15),del(5)(q22q31), +8,psudic(17;3)(p13;p12) [16]/nonclonal w/clonal abnormalities[2]/46,XX[2]	3	CRi	2	4
11	71/F	No	Relapsed	10 mo	46, XX	3	SD	0	1
12	58/F	No	Relapsed from CR2	CR1 = 31mo CR2 = 13mo	46,XX	3	SD	0	2
13	70/M	No	Relapsed	CR1 = 19mo	46,XY	3	CRi	1	5+

Case series table describing cytogenetics and outcomes of each patient enrolled. SD, stable disease; PD, progressive disease, CR, complete remission.